{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:45:14Z","timestamp":1761630314504},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,8,28]],"date-time":"2003-08-28T00:00:00Z","timestamp":1062028800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"DOI":"10.1186\/1471-2474-4-19","type":"journal-article","created":{"date-parts":[[2003,9,11]],"date-time":"2003-09-11T06:51:37Z","timestamp":1063263097000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report"],"prefix":"10.1186","volume":"4","author":[{"given":"Salvatore","family":"Gulli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Bocchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Morgante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Sangari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Filippo","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,8,28]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/0140-6736(90)92643-V","volume":"335","author":"Disease International Study Group for Behce","year":"1990","unstructured":"International Study Group for Behcet's Disease: Criteria for diagnosis of Behcet's disease. Lancet. 1990, 335: 1078-1080. 10.1016\/0140-6736(90)92643-V.","journal-title":"Lancet"},{"key":"55_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","volume":"341","author":"T Sakane","year":"1999","unstructured":"Sakane T, Takeno M, Suzuki N, Inaba G: Behcet's disease. N Engl J Med. 1999, 341: 1284-1291. 10.1056\/NEJM199910213411707.","journal-title":"N Engl J Med"},{"issue":"suppl","key":"55_CR3","first-page":"S6","volume":"19","author":"A Gul","year":"2001","unstructured":"Gul A: Behcet's disease: an update on the pathogenesis. Clin Exp Rheumatol. 2001, 19 (suppl): S6-S12.","journal-title":"Clin Exp Rheumatol"},{"key":"55_CR4","first-page":"128","volume":"24","author":"B Turan","year":"1997","unstructured":"Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM: Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease: soluble TNFR-75 as a biologic marker of disease activity. J Rheumatol. 1997, 24: 128-132.","journal-title":"J Rheumatol"},{"key":"55_CR5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1365-2249.1997.274-ce1159.x","volume":"107","author":"N Yamashita","year":"1997","unstructured":"Yamashita N, Kaneoka H, Kaneko S: Role of gammadelta T lymphocytes in the development of Behcet's disease. Clin Exp Immunol. 1997, 107: 241-247. 10.1111\/j.1365-2249.1997.274-ce1159.x.","journal-title":"Clin Exp Immunol"},{"key":"55_CR6","first-page":"687","volume":"13","author":"L Emmi","year":"1995","unstructured":"Emmi L, Brugnolo F, Salvati G, Marchione T: Immunopathological aspects of Behcet's disease. Clin Exp Rheumatol. 1995, 13: 687-691.","journal-title":"Clin Exp Rheumatol"},{"key":"55_CR7","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatic arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999, 354: 1932-1939. 10.1016\/S0140-6736(99)05246-0.","journal-title":"Lancet"},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1053\/sarh.2001.19819","volume":"30","author":"VG Kaklamani","year":"2001","unstructured":"Kaklamani VG, Kaklamanis PG: Treatment of Behcet's disease: an update. Semin Arthritis Rheum. 2001, 30: 299-312. 10.1053\/sarh.2001.19819.","journal-title":"Semin Arthritis Rheum"},{"issue":"suppl II","key":"55_CR9","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1136\/ard.61.suppl_2.ii51","volume":"61","author":"PP Sfikakis","year":"2002","unstructured":"Sfikakis PP: Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 2002, 61 (suppl II): S51-S53.","journal-title":"Ann Rheum Dis"},{"key":"55_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/ard.60.6.637","volume":"60","author":"PH Goossens","year":"2001","unstructured":"Goossens PH, Verburg RJ, Breedveld FC: Remission of Behcet's syndrome with tumour necrosis factor a blocking therapy. Ann Rheum Dis. 2001, 60: 637-10.1136\/ard.60.6.637.","journal-title":"Ann Rheum Dis"},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","volume":"40","author":"LP Robertson","year":"2001","unstructured":"Robertson LP, Hickling P: Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with Infliximab. Rheumatology. 2001, 40: 473-474. 10.1093\/rheumatology\/40.4.473.","journal-title":"Rheumatology"},{"key":"55_CR12","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1136\/ard.61.3.283-a","volume":"61","author":"M Rozembaum","year":"2002","unstructured":"Rozembaum M, Rosner I, Portnoy E: Remission of Behcet's syndrome with TNF alpha blocking treatment. Ann Rheum Dis. 2002, 61: 283-284. 10.1136\/ard.61.3.283-a.","journal-title":"Ann Rheum Dis"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/gast.2001.22556","volume":"120","author":"PV Hassard","year":"2001","unstructured":"Hassard PV, Binder SW, Nelson V, Vasiliauskas EA: Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology. 2001, 120: 995-999.","journal-title":"Gastroenterology"},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gut.49.5.725","volume":"49","author":"SP Travis","year":"2001","unstructured":"Travis SP, Czajkowski M, Mc Govern DP, Watson RG, Bell AL: Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001, 49: 725-728. 10.1136\/gut.49.5.725.","journal-title":"Gut"},{"key":"55_CR15","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10350-004-6506-4","volume":"46","author":"MT Kram","year":"2003","unstructured":"Kram MT, May LD, Goodman S, Molinas S: Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum. 2003, 46: 118-121.","journal-title":"Dis Colon Rectum"},{"key":"55_CR16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","volume":"358","author":"PP Sfikakis","year":"2001","unstructured":"Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN: Effect of Infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001, 358: 295-296. 10.1016\/S0140-6736(01)05497-6.","journal-title":"Lancet"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(01)06677-6","volume":"358","author":"S Munoz-Fernandez","year":"2001","unstructured":"Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E: Effect of Infliximab on threatening panuveitis in Behcet's disease. Lancet. 2001, 358: 1644-10.1016\/S0140-6736(01)06677-6.","journal-title":"Lancet"},{"key":"55_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/ard.61.6.560","volume":"61","author":"G Triolo","year":"2002","unstructured":"Triolo G, Vadala' M, Accardo Palumbo A, Ferrante A, Ciccia F, Giardina E, Citarrella P, Lodato G, Licata G: Anti-tumour necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis. 2002, 61: 560-561. 10.1136\/ard.61.6.560.","journal-title":"Ann Rheum Dis"},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/rheumatology\/41.10.1213-b","volume":"41","author":"C Estrach","year":"2002","unstructured":"Estrach C, Mpofu S, Moots RJ: Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford). 2002, 41: 1213-1214. 10.1093\/rheumatology\/41.10.1213-b.","journal-title":"Rheumatology (Oxford)"},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1006\/cyto.1995.0029","volume":"7","author":"BJ Scallon","year":"1995","unstructured":"Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J: Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995, 7: 251-259. 10.1006\/cyto.1995.0029.","journal-title":"Cytokine"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-4-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2474-4-19\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-4-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2474-4-19.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T15:32:46Z","timestamp":1726241566000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-4-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8,28]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2003,12]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1186\/1471-2474-4-19","relation":{},"ISSN":["1471-2474"],"issn-type":[{"type":"electronic","value":"1471-2474"}],"subject":[],"published":{"date-parts":[[2003,8,28]]},"assertion":[{"value":"18 March 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"19"}}